Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) Director David Altshuler unloaded 5,000 shares of the stock in a transaction that occurred on Thursday, July 31st. The shares were sold at an average price of $89.59, for a total value of $447,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

VRTX has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Vertex Pharmaceuticals has an average rating of “Hold” and a consensus price target of $102.82.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 1.55% during mid-day trading on Friday, hitting $87.53. The stock had a trading volume of 2,479,512 shares. Vertex Pharmaceuticals has a one year low of $58.06 and a one year high of $99.74. The stock’s 50-day moving average is $89.68 and its 200-day moving average is $78.06. The company’s market cap is $20.773 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.61) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter last year, the company posted ($0.03) earnings per share. Vertex Pharmaceuticals’s revenue was down 55.5% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals will post $-2.85 EPS for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.